NDA FOR OMAVELOXOLONE FOR PATIENTS WITH FRIEDREICH’S ATAXIA UNDER REVIEW WITH PDUFA
DATE OF FEBRUARY 28, 2023
FDA DOES NOT PLAN TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS THE OMAVELOXOLONE
NDA AND THE LATE CYCLE MEETING HAS BEEN COMPLETED
PROVIDES UPDATE ON COMMERCIAL PREPARATION
PLANO, Texas—November 8, 2022 (BUSINESS WIRE)—Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the
“Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the
third quarter of 2022 and provided an update on the Company’s business operations and clinical development
programs.
Read the Full article here
Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results And Provides An Update On Clinical Development Programs
- Details
- Category: Scientific News